Dr. Matt Davids of the Dana Farber Cancer Institute joins Healthcare Unfiltered EXPRESS to share his data-solidified insights on navigating the treatment of relapsed/refractory (R/R) CLL, considering the welcome advances the field has witnessed in treating front-line disease. Check it out, subscribe, rate, and join the conversation.